tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital
PremiumThe FlyPyxis Oncology price target lowered to $5 from $8 at RBC Capital
3M ago
Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
Premium
Ratings
Maintaining a Buy on Pyxis: Early MICVO Efficacy, Dose Optimization, and 2026 Data as the Next Major Catalyst
3M ago
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
Premium
The Fly
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
3M ago
Pyxis Oncology files $350M mixed securities shelf
PremiumThe FlyPyxis Oncology files $350M mixed securities shelf
4M ago
Pyxis Oncology price target raised to $8 from $5 at Stephens
Premium
The Fly
Pyxis Oncology price target raised to $8 from $5 at Stephens
4M ago
Pyxis Oncology Reports Increased Losses Amid Development Focus
Premium
Company Announcements
Pyxis Oncology Reports Increased Losses Amid Development Focus
4M ago
Pyxis Oncology resumed with a Buy at Stifel
PremiumThe FlyPyxis Oncology resumed with a Buy at Stifel
5M ago
Pyxis Oncology’s Promising Study on PYX-201 and Pembrolizumab in Advanced Solid Tumors
Premium
Company Announcements
Pyxis Oncology’s Promising Study on PYX-201 and Pembrolizumab in Advanced Solid Tumors
5M ago
Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment
Premium
Company Announcements
Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100